Cedars Sinai
‘Spectrum of risk’ exists for papillary thyroid carcinoma

Aggressive papillary thyroid carcinoma variants appeared associated with a wide range of survival outcomes, suggesting greater emphasis should be placed on tailored treatment approaches for patients with histologically and prognostically distinct subtypes, according to study results published in JAMA Oncology.
Patient-reported outcomes could help guide selection of treatment for localized prostate cancer
FDA committee votes against approval of Tookad for localized prostate cancer
New treatments offer ‘glimmers of optimism,’ possible cure for Cushing’s disease
Teprotumumab significantly improves proptosis in thyroid eye disease
Medical Management of IBS is Improving With Time
Department of Defense awards $10 million to Cedars-Sinai for pancreatic disease research
Out for Blood: Biomarkers Paving the Road to Personalized Medicine for Rheumatic Diseases
Cancer may be associated with broken heart syndrome
Nivolumab shows limited activity in untreated brain metastases from renal cell carcinoma
Nivolumab demonstrated limited activity among patients with untreated brain metastases from clear cell renal cell carcinoma who experienced progression after vascular endothelial growth factor receptor-directed therapy, according to results of a phase 2 study published in Journal of Clinical Oncology.